Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients.

中文翻译：

---

急性髓性白血病强化治疗的结果：对 HARMONY 联盟二十年数据的分析。


自 2017 年以来，靶向治疗联合常规强化化疗已开始改善急性髓系白血病 （AML） 患者的预后。然而，即使在这些创新之前，强化化疗的结果就已经改善，这尚未得到广泛研究。因此，我们使用了 HARMONY 联盟的大型泛欧多中心数据集来评估二十年来的治疗时间依赖性结果。在 5359 名 AML 患者中，我们比较了从 1997 年到 2016 年连续四个 5 年日历期间强化诱导治疗对结果的影响。在此期间，AML 患者的 5 年生存率显著提高，在不同的遗传风险组中也是如此。特别是，随着时间的推移，60 天的死亡率从 13.0% 下降到 4.7%。日历期对结局的独立影响在多变量模型中得到证实。记录了患者的改善。